Johnson & Johnson Pitches Final Arguments to Approve $10B Talc Bankruptcy Plan
In Friday's hearing, which lasted 10 hours, U.S. Bankruptcy Judge Christopher Lopez heard closing arguments in Johnson & ...
Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors
Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...
Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition
JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.
Johnson & Johnson price target raised to $171 from $159 at BofA
BofA raised the firm’s price target on Johnson & Johnson (JNJ) to $171 from $159 and keeps a Neutral rating on the shares. For the last ...